Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The AchromoPhage Trial
NCT07275905Phase 1Recruiting
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Modality
- Single Strain Products, Multi-strain Products
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AchromoPhage in cystic fibrosis (CF) and Achromobacter infection (3 arms). Primary endpoint: Incidence of treatment-related Grade >=4 adverse events or treatment-limiting toxicities at 42 days. Started Aug 2026; status: recruiting.
02
Drugs
AchromoPhage
03
Conditions
cystic fibrosis (CF)Achromobacter infection
Beyond the preview
Go deeper on NCT07275905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275905.